COMMUNIQUÉS West-GlobeNewswire

BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress

06/09/2019 - 07:50

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases [...]

European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer

06/09/2019 - 07:03

Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung [...]

European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer

06/09/2019 - 07:00

The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC) Decision based on data showing that the Tecentriq plus [...]

SunGen Pharma Receives Seventh ANDA Approval from US FDA

06/09/2019 - 03:25

PRINCETON, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced it [...]

Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock

06/09/2019 - 02:34

SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the pricing of its [...]

Ascent Industries Provides Bi-Weekly Default Status Report

06/09/2019 - 01:42

VANCOUVER, British Columbia, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Ascent Industries Corp. ( CSE: ASNT ) (“ Ascent ” or the “ Company ”) is providing this bi-weekly default status report in accordance with National Policy [...]

Zealand Pharma major shareholder announcement: Van Herk Investments

05/09/2019 - 23:30

Company announcement – No. 31 / 2019 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, September 5, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen- [...]

President & CEO of Nova Leap Health Corp. to Present at the 12th Annual LD Micro Main Event

05/09/2019 - 23:09

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Sept. 05, 2019 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a 2019 [...]

Veloxis Increases Share Capital in Connection with Exercise of Warrants

05/09/2019 - 22:53

Company Release no. 15/2019 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 05 September 2019 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company [...]

Rockwell Medical, Inc. Appoints Industry Veteran John P. McLaughlin to Board of Directors

05/09/2019 - 22:30

WIXOM, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an [...]

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

05/09/2019 - 22:30

CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79, The Duchenne [...]

Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05/09/2019 - 22:05

SEATTLE, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, [...]

Caladrius Biosciences to Participate at the Upcoming September Conferences

05/09/2019 - 22:05

BASKING RIDGE, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements [...]

Microbot Medical to Demonstrate a Working Prototype of its Self-Cleaning Shunt at the Rodman & Renshaw Annual Global Investment Conference

05/09/2019 - 22:05

HINGHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- At the upcoming Rodman & Renshaw Global Investment Conference, Harel Gadot, CEO, President and Chairman of Microbot Medical Inc. (Nasdaq: MBOT), will demonstrate a [...]

Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum

05/09/2019 - 22:05

NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious [...]

Avid Bioservices Reports Financial Results for First Quarter Fiscal 2020 and Recent Developments

05/09/2019 - 22:05

-- Achieved First Quarter Revenue of $15.3 Million; Reaffirms Fiscal 2020 Projected Revenue of $64 to $67 Million -- -- Signed Two Contract Manufacturing Agreements with New and Existing Customers -- TUSTIN, Calif., [...]

Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society

05/09/2019 - 22:01

- Data analyses from clinical trials to highlight eptinezumab’s efficacy and early, sustained quality of life improvements in the prevention of chronic migraine - - Preclinical data also to be presented for ALD1910, [...]

Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

05/09/2019 - 22:01

Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods Proprietary capabilities to be integrated into Neon’s RECON® bioinformatics [...]

BridgeBio Pharma’s Origin Biosciences Presents New Data on the Natural History of Molybdenum Cofactor Deficiency (MoCD) Type A at the Society of the Study of Inborn Errors of Metabolism (SSIEM) Conference

05/09/2019 - 22:00

This landmark study is a comprehensive global survey of the natural history of MoCD Type A Results continue to suggest urgent need for new therapies in MoCD Type A, with median survival of <4 years and rapid disease [...]